期刊
JOURNAL OF CONTROLLED RELEASE
卷 329, 期 -, 页码 833-846出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2020.10.015
关键词
Miriplatin ultrasmall dots; DNA damage; Triple negative breast cancer; Circulating tumor cells; Cancer stem cell (CSC)-like cells; Metastasis
资金
- American Cancer Society [RGS15-026-01-CSM]
- Shared Animal Imaging and Histology Resources of the University of Kentucky Markey Cancer Center [P30CA177558]
The study developed a novel ultrasmall Pt(II) dot that displayed superior DNA damage capability and significantly reduced the CSC-like properties of TNBC cells, as well as targeted circulating tumor cells in vivo to suppress breast cancer metastasis. The ultrasmall Pt(II) dots represent a promising therapeutic agent for reducing cancer metastasis through metal-based nanomedicines.
No effective therapy is yet available to treat triple negative breast cancer (TNBC), which has poor prognosis due to frequent metastasis. Cancer stem cells (CSCs) or CSC-like cells play crucial roles in cancer metastasis and are exceptionally tolerant with genetic lesions. The extent of DNA damages has an important impact on the fate of CSCs. Despite the importance of platinum [Pt(II)] agents in cancer therapy, accumulating reports showed the treatment failure of conventional Pt(II) drugs, which is likely due to their inadequate DNA damage effects. Miriplatin is a clinically approved drug only being locally-used for treating liver cancer. In this study, we developed a novel ultrasmall Pt(II) dot (uPtD) from miriplatin and encapsulated it into our recently-reported integrin alpha 5(ITGA5) active targeting nanoparticles (uPtDs NPs) and tested their therapeutic efficacy against TNBC metastasis. It was found that uPtDs NPs displayed a superior DNA damage capability via enhanced-interactions with DNA and a significantly stronger effect in reducing CSC-like property of TNBC cells, compared to conventional cisplatin and miriplatin. Mechanistically, the severe DNA damages induced by uPtDs NPs activated the CHK1/2-CDC25A-cyclin A/E pathway to induce cell cycle arrest. Moreover, uPtDs NPs could target the in vivo circulating tumor cells (CTCs) to suppress TNBC lung metastasis. Given the desired-safety profile of miriplatin, the uPtDs represent a promising therapeutic agent of the metal-based nanomedicines to reduce cancer metastasis. Significance: The miriplatin ultrasmall dots developed from clinically-prescribed miriplatin may serve as a potent systemically-administered agent to target CTCs and reduce cancer metastasis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据